Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Status:
Completed
Trial end date:
2018-12-10
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well carboplatin and combination chemotherapy with
or without veliparib works in treating patients with stage IIB-IIIC breast cancer. Drugs used
in chemotherapy, such as paclitaxel, carboplatin, doxorubicin hydrochloride, and
cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing
the cells or by stopping them from dividing. Veliparib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. It is not yet known whether giving
carboplatin and combination chemotherapy are more effective with or without veliparib is more
effective in treating breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University